Enhancing endogenous ANP-BNP/NPRA signaling has proven to be critical in the first line of therapeutic targets for hypertension, cardiac dysfunction, and CHF in decades (McMurray et al., 2014). The gene discussed is NPPA; the disease is congestive heart failure.